Masonic Cancer Center

A Comprehensive Cancer Center designated by the National Cancer Institute

Find a Clinical Trial

Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help
Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 2013CG034 Principal Investigator Greengard, Emily
Phase Pilot
Age Group Both Scope National
Secondary Protocol No. ANBL12P1
Title MT2013-14: COG ANBL12P1: Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma
Applicable Disease Sites Any Site
Other Endocrine System
Soft Tissue
Drugs Involved CISPLATIN (PLATINOL, CDDP)
CYCLOPHOSPHAMIDE (CYTOXAN, NEOSAR)
DOXORUBICIN HYDROCHLORIDE (ADRIAMYCIN)
ETOPOSIDE (VP-16)
TOPOTECAN
VINCRISTINE (ONCOVIN)
Status Open
Participating Institutions Masonic Cancer Center
Treatment Type Treatment
Contact Jensina Ericksen Phone:6126257908
Email:erick377@umn.edu
  • ©2013 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on